- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02634138
Neuromuscular Electrical Stimulation in Patients With Critical Limb Ischaemia
Study Overview
Status
Intervention / Treatment
Detailed Description
The circulation of blood around the body is dependent on effective pumping of the heart. Patients with arterial insufficiency are known to have poor circulation in their lower legs and feet leading to various complications such as swelling and painful legs and reduced healing of injuries.
Peripheral arterial disease (PAD) can be defined as a narrowing of the arteries reducing blood flow. It is most commonly due to atherosclerosis, and has associations with heart disease, stroke, and diabetes. Its incidence is estimated at 7-14% in the general population, increasing with age to about 20% in the over-seventies. It is associated with effects on mobility, skin condition and quality of life. Symptoms include pain in the legs on walking (intermittent claudication), pain at rest (particularly at night), gangrene, and limb loss. Management of PAD is based on encouraging exercise, and modification of risk factors such as smoking, high blood pressure, high cholesterol and diabetes.
In patients with PAD, exercise tolerance is often limited. Severe symptoms and disease can be treated via such as balloon angioplasty, stenting or surgical bypass, but these procedures have risk. There also remains a percentage of patients who are not suitable for revascularisation, and have only a few options such as amputation available to them.
Some trials have shown that increasing the blood flow in the legs over time using medical devices (intermittent pneumatic compression, muscle stimulators), in addition to maximal medical and surgical therapy, can increase claudication distance, absolute walking distance, decrease rest pain, and reduce amputation rates. In the investigators unit it has become apparent that there are an increasing number of medical devices available for circulatory support, either as an inpatient, out-patient, or a member of the general public. The supporting evidence for these is variable in scientific and clinical content or relevance, and requires clinical trials to evaluate further.
Revitive activates the pumping action of leg muscles by providing electrical muscle stimulation to cause foot muscle contraction and relaxation which squeezes blood back towards the heart, improving circulation.
The investigators wish to evaluate whether NMES using this device has the same beneficial effects in patients with critical limb ischaemia.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, W6 8RF
- Imperial College London - Charing Cross Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Willing, able, and committed to participate in the procedures for the full length of the study.
- All ethnic groups, male or female above the age of 18 years.
- Diagnosis of non-reconstructable arterial disease and critical limb ischaemia (with a minimum of duplex ultrasound and an MDT discussion to have reached this diagnosis)
- Be of non-childbearing potential; OR using adequate contraception and have a negative urine pregnancy test result within 24 hours if appropriate before using the study device.
- Blood pressure currently under moderate control (< 160/100mmHg)
- History of uncomplicated cardiovascular events beyond 3 months.
- No current foot ulceration
Exclusion Criteria:
Patients meeting any of the following criteria are to be excluded:
- Has an unstable condition (eg, psychiatric disorder, a recent history of substance abuse) or otherwise thought to be unreliable or incapable of complying with the study protocol.
- Has any metal implants
- Pregnant
- Has peripheral neuropathy
- Has a cardiac pacemaker or defibrillator device
- Has recent lower limb injury or lower back pain
- Has current foot ulceration or other skin ulcers
- Has foot deformities
- Has any disorder that, in the opinion of the Investigator, might interfere with the conduct of the study
- Ankle-Brachial Pressure Index >0.9
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention
Revitive IX Neuromuscular Electrical Stimulation Device
|
A foot plate Neuromuscular Electrical Stimulation Device
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain Score
Time Frame: 6 weeks
|
Change in pain score with device use over a 6 week period.
Measure by a visual analogue scale of pain with 0 = no pain and 10 = maximum pain
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Major amputation rate
Time Frame: 6 weeks
|
Identify if and number of major amputations carried out during study period.
|
6 weeks
|
Flow rate in Femoral Artery
Time Frame: Day 1 then at 6 weeks
|
Duplex ultrasound guided measurement of femoral artery flow rate whilst using the device on day 1 and then 6 weeks later during follow up visit.
|
Day 1 then at 6 weeks
|
Femoral artery diameter
Time Frame: Day 1 and at 6 weeks
|
Duplex ultrasound guided measurement of femoral artery diameter whilst using the device on day 1 and then 6 weeks later during follow up visit.
|
Day 1 and at 6 weeks
|
Disease specific questionnaire - VascuQoL
Time Frame: Day 1 and at 6 weeks
|
Change of disease specific Quality of Life (QoL) measure from baseline to 6 weeks.
|
Day 1 and at 6 weeks
|
Short Form - 36 (SF-36)
Time Frame: Day 1 and at 6 weeks
|
Change ofSF-36 Quality of Life (QoL) score from Day 1 to 6 weeks.
|
Day 1 and at 6 weeks
|
EuroQol - EQ5D
Time Frame: Day 1 and at 6 weeks
|
Change of EQ5D Quality of Life (QoL) score from Day 1 to 6 weeks.
|
Day 1 and at 6 weeks
|
Patient compliance using diary of device use
Time Frame: 6 weeks
|
Check the frequency of device use over the 6 week study period.
|
6 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 14HH2036
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Arterial Disease
-
University of NebraskaNot yet recruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
CID S.p.A.Meditrial Europe Ltd.Not yet recruitingPeripheral Arterial Occlusive Disease | Peripheral Artery DiseaseItaly
-
Marissa JarosinskiRecruitingPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Clopidogrel, Poor Metabolism of | Artery DiseaseUnited States
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
Vascuros Medical Pte LtdNovella ClinicalUnknownPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery DiseaseSingapore, Belgium, Germany
-
Western Vascular Institute, IrelandRecruitingPeripheral Arterial Occlusive DiseaseIreland
-
Jena University HospitalAngioDroid s.r.l., Bologna (Italy)CompletedPeripheral Arterial Occlusive DiseaseGermany
-
Seoul National University HospitalAstellas Pharma Korea, Inc.CompletedPeripheral Arterial Occlusive DiseaseKorea, Republic of
-
Heidelberg UniversityTerminatedPeripheral Arterial Occlusive DiseaseGermany
-
Johann Wolfgang Goethe University HospitalSuspendedPeripheral Arterial Occlusive DiseaseGermany
Clinical Trials on Revitive IX
-
Imperial College LondonCompletedIntermittent Claudication | Peripheral Vascular Disease | Lower Limb Arterial DiseaseUnited Kingdom
-
Imperial College LondonActegy Ltd.CompletedVaricose Veins | Venous Insufficiency | OedemaUnited Kingdom
-
Imperial College LondonActegy Ltd.CompletedVaricose Veins | Venous Insufficiency | Venous Stasis
-
Imperial College LondonCompleted
-
Imperial College Healthcare NHS TrustWithdrawnPeripheral Arterial Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Femoral Popliteal OcclusionUnited Kingdom
-
Ixchelsis LimitedCompletedPremature EjaculationUnited States
-
Imperial College LondonActegy Ltd.Not yet recruitingDiabetic Neuropathies | Diabetic Peripheral Neuropathy | Diabetic Polyneuropathy | Diabetic ComplicationUnited Kingdom
-
Bioverativ Therapeutics Inc.Swedish Orphan BiovitrumCompletedSevere Hemophilia BSweden, United States, France, Italy, Russian Federation, United Kingdom, Germany, China, Poland, Japan, Australia, Brazil, Canada, India, South Africa, Hong Kong, Belgium
-
Baxalta now part of ShireBaxalta Innovations GmbH, now part of ShireCompleted
-
Ixchelsis LimitedCompletedHealthy ParticipantsUnited Kingdom